Discovering a Common Goal,
Discovering a Cure

CONTACT  |  DONATE  |  E-NEWSLETTER  | 
  
DRUG NEWS

Research News
Drug News
Conference News
< Home



Astrazeneca and University of Cambridge Partner on Neurodegenerative Disease Research
October 28, 2014
Astrazeneca, together with its biologics arm, Medimmune, has expanded its strategic alliance with University of Cambridge beyond oncology into research and development for neurodeg...

Two Leading Neuroscientists Join Biogen-Idec to Advance Neurodegenerative Disease Research
October 23, 2014
Biogen-Idec is taking further steps to advance its research and development efforts in neurodegenerative diseases. After appointing Donald Johns to head the ALS iHUB in August, Bio...

Cytokinetics Planning Phase III Clinical Trial of Tirasemtiv for ALS
October 21, 2014
Based on promising effects on respiratory function, and follow-up discussions with statisticians, clinicians and the US Food and Drug Administration, Cytokinetics announced its dec...

Genervon Announces Promising Results of its Phase IIb Trial of GM6 in ALS and PD
October 20, 2014
In July this year, Genervon announced promising results of its Phase IIb clinical trial of GM6 in ALS and Parkinson's disease (PD) based on biomarker data from the trial. The biote...

Fast-Track Designation Granted to NurOwn for Treating ALS
October 17, 2014
The U.S. Food and Drug Administration (FDA) has granted Fast-Track designation to BrainStorm Cell Therapeutics’ NurOwn for treating ALS. The company’s stem cell therapy consist...





The ALS Forum was developed by Prize4Life, Inc.
 
© 2014 Prize4Life, Inc.
Identified content provided through
a partnership with the Alzforum